Oruka Therapeutics, Inc. (ORKA NASDAQ) stock market data APIs
$16.2881
1.57(9.6%)
as of September 17, 2025
Try our APIs with
free plan!
Oruka Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prev. Close
16.2881
Open
17.8593
High
18.325
Low
15.7932
52 wk Range
5.49-31.13
Market Cap
558 M
Shares Outstanding
37 451 K
EPS
-0.46
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oruka Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oruka Therapeutics, Inc. data using free add-ons & libraries
Get Oruka Therapeutics, Inc. Fundamental Data
Oruka Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.4325
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oruka Therapeutics, Inc. News
New
Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker
Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments
Oruka Therapeutics, Up 10%, Is Trying To Take On AbbVie's Biggest Moneymaker
Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker
Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments
Sector Update: Health Care Stocks Rise Premarket Wednesday
Health care stocks were rising premarket Wednesday, with the iShares Biotechnology ETF (IBB) 0.5% hi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
